Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PDE1A | P54750 | 1/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8552154 | 0.86 | KDM4E (0.38) | LMNASMN1; SMN2MAPTKDM4EPKM | |
| SCHEMBL581638 | 0.79 | LMNA (0.37) | LMNAMAPTKDM4EHTTALDH1A1 | |
| SCHEMBL3606506 | 0.77 | GOT1 (0.32) | — | |
| SCHEMBL29537275 | 0.74 | MAPT (0.49) | LMNASMN1; SMN2MAPTKDM4EPKM | |
| SCHEMBL580414 | 0.74 | MAPT (0.49) | LMNASMN1; SMN2MAPTKDM4EPKM | |
| SCHEMBL1316871 | 0.70 | PTGS1 (0.41) | LMNASMN1; SMN2KDM4EPKMHTT | |
| SCHEMBL8551380 | 0.69 | LMNA (0.45) | LMNASMN1; SMN2MAPTKDM4EPKM | |
| SCHEMBL28471578 | 0.68 | KDM4E (0.44) | LMNASMN1; SMN2MAPTKDM4EPKM | |
| SCHEMBL4864061 | 0.68 | HTT (0.60) | LMNASMN1; SMN2MAPTKDM4EHTT | |
| SCHEMBL9138181 | 0.67 | KDM4E (0.47) | LMNASMN1; SMN2MAPTKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242961-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-1984353-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2418209-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20140066430-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2418209-A1 | Aurora kinase modulators and method of use | Amgen Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110263530-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-8022221-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7560551-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1984353-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007087276-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066430-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, AURKB | LMNA 620/4885SMN1; SMN2 3923/4885MAPT 2283/4885 |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | LMNA 637/4885SMN1; SMN2 3987/4885MAPT 1958/4885 |
| US-20110263530-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, AURKB | LMNA 620/4885SMN1; SMN2 3923/4885MAPT 2283/4885 |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, AURKB | LMNA 620/4885SMN1; SMN2 3923/4885MAPT 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.